Squalamine-lactate-MSI-1256F-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESqualamine lactateCat. No.: HY-16467CAS No.: 320725-47-1Synonyms: MSI-1256F分式: CHNOS分量: 718.04作靶點(diǎn): Bacterial作通路: Anti-infection儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 36.66 mg/mL (5

2、1.06 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.3927 mL 6.9634 mL 13.9268 mL5 mM 0.2785 mL 1.3927 mL 2.7854 mL10 mM 0.1393 mL 0.6963 mL 1.3927 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Squalamine lactate種從鯊體內(nèi)分到的氨 甾醇，具有抗

3、活性，同時(shí)可于新管性年齡相關(guān)性黃斑變性的研究。體外研究Squalamine lactate has a more generalized effect on the cellular signaling cascade that is common to bothVEGF and other growth factors 1. Squalamine blocks the action of VEGF and integrin expression, thereby1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEinhibiting angiog

4、enesis, when bound to calmodulin 2.體內(nèi)研究 Squalamine is ineffective when administered intravitreally and therefore requires intravenous dosing.However, systemic dosing has yielded promising results in rats as well as humans 2.REFERENCES1. Hussain RM, et al. Emerging vascular endothelial growth factor

5、antagonists to treat neovascular age-related macular degeneration.Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246.2. Emerson MV, et al. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008Jun;2(2):377-88.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-5